Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc.（CGTX）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · CGTX · 截至 2025年9月30日
股东结构概览
69
机构持有人数
▲ 21 vs Q2
$28.72M
机构持仓总市值
▲ $25.21M vs Q2
73.58M
总流通股
freeFloat 80.37%
21.27M
13F 申报持股数
▲ 10.03M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
CGTX 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BIOS CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 6.00M | 9.42% | 9.42% | $8.10B | Nov 12, 2025 | — held |
DAVENPORT & CO LLC biological products, (no diagnostic substances) | 2.69M | 4.22% | 4.22% | $3.63B | Oct 15, 2025 | NEW |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.68M | 4.21% | 4.21% | $3.62B | Nov 7, 2025 | ▲ 1.38M |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.20M | 1.88% | 1.88% | $1.62B | Nov 14, 2025 | NEW |
CHESCAPMANAGER LLC biological products, (no diagnostic substances) | 997.0K | 1.57% | 1.57% | $1.35B | Nov 14, 2025 | ▲ 493.8K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 968.7K | 1.52% | 1.52% | $1.31B | Nov 12, 2025 | ▲ 891.8K |
JANE STREET GROUP, LLC biological products, (no diagnostic substances) | 926.1K | 1.45% | 1.45% | $1.25B | Nov 14, 2025 | ▲ 912.9K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 713.5K | 1.12% | 1.12% | $963.23M | Nov 13, 2025 | ▲ 617.1K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 712.7K | 1.12% | 1.12% | $962.53M | Nov 12, 2025 | ▲ 344.0K |
HILTON CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 581.1K | 91.25% | 91.25% | $784.55M | Nov 12, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
19
增持
+5.42M 股20
新建仓
首次建仓3
减持
−171.0K 股0
清仓
完全退出净股数变化（前50家）
+5.25M
+5.42M / −171.0K
净新增持仓人
+36
新建 20 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
CGTX 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
3
买入笔数
5
卖出笔数
0.60
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Doyle John Brendan Chief Financial Officer | May 1, 2026 | Tax Withhold | 8,567 | $1.28 | $11.0K | 618.9K | Form 4 ↗ |
Doyle John Brendan Chief Financial Officer | Apr 16, 2026 | Purchase | 10,000 | $1.13 | $11.3K | 627.5K | Form 4 ↗ |
Ricciardi Lisa CEO & President | Apr 16, 2026 | Purchase | 9,175 | $1.10 | $10.1K | 1.72M | Form 4 ↗ |
Caggiano Anthony Chief Medical Officer | Apr 16, 2026 | Purchase | 10,000 | $1.11 | $11.1K | 874.9K | Form 4 ↗ |
Ricciardi Lisa CEO & President | Feb 15, 2026 | Tax Withhold | 5,850 | $1.12 | $6.6K | 1.71M | Form 4 ↗ |
Doyle John Brendan Chief Financial Officer | Feb 15, 2026 | Tax Withhold | 1,560 | $1.12 | $1.7K | 617.5K | Form 4 ↗ |
Caggiano Anthony Chief Medical Officer | Feb 15, 2026 | Tax Withhold | 4,680 | $1.12 | $5.2K | 864.9K | Form 4 ↗ |
Ricciardi Lisa CEO & President | Feb 3, 2026 | Award | 800,000 | — | — | 1.79M | Form 4 ↗ |
Ricciardi Lisa CEO & President | Feb 3, 2026 | Tax Withhold | 26,036 | $1.12 | $29.2K | 1.76M | Form 4 ↗ |
Ricciardi Lisa CEO & President | Feb 4, 2026 | Tax Withhold | 51,704 | $1.03 | $53.3K | 1.71M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Cognition Therapeutics, Inc.（CGTX）主要由机构投资者持有，机构持股比例约为 28.9%。公司内部人员持股约 19.63%，散户及公众持股约占剩余的 51.46%。
Cognition Therapeutics, Inc. 最大机构股东为 BIOS CAPITAL MANAGEMENT, LP，截至 September 30, 2025 持有约 6.00 million 股，占总流通股的 9.42%。
目前共有 69 家机构持有 CGTX 股票，合计持仓市值约 $28,724,649，数据来源为最新 SEC 13F 申报。
常见问题
CGTX ownershipCognition Therapeutics, Inc.（CGTX）主要由机构投资者持有，机构持股约 28.9%。最大股东为 BIOS CAPITAL MANAGEMENT, LP，持股比例 9.42%。内部人员持股约 19.63%。数据来源 SEC Form 13F，截至 September 30, 2025。